Merck's Lung Cancer Combo Outperforms Keytruda in Late-Stage Trial
Merck (MRK) reported that a lung cancer treatment developed with Kelun-Biotech outperformed its own anti-PD-1 therapy, Keytruda, in a late-stage trial. The results could influence future treatment options and impact Merck's market position.
Tickers: $MRK
Topics: antibody drug conjugate (ADC) biopharma cancer treatment Keytruda